๐Ÿ”ฌDeep Research

ACRV โ€” Acrivon Therapeutics Inc ยท catalysts, narrative & risks

ยท17 sourcesACRV forecast โ†’

Acrivon Therapeutics, Inc. (ACRV) โ€” Research Summary (as of 2026-10-03)

Company Snapshot

Acrivon Therapeutics, Inc. (Nasdaq: ACRV) is a clinical-stage biopharmaceutical company developing precision medicines for cancer patients using its proprietary Acrivon Predictive Precision Proteomics (AP3) generative phosphoproteomics platform [2], [6], [9]. The company was founded in 2018 and is led by CEO Peter Blume-Jensen, M.D., Ph.D. [2], [9]. As of the Oct 2, 2026 close, the stock traded at ~$1.99 with a market capitalization of ~$85.3 million [6], [9].


AI-assisted research from the K3vl4r desk โ€” not personalized investment advice. More research โ†’